Myriad Genetics grants Jennifer Lynne Fox 139,267 options

The options vest and become exercisable in full in 2029, subject to Fox's continued service through the vesting date and the plan and award-agreement terms.

Available on EDGAR 11/09/2026 - 04:13 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:13 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Myriad Genetics Inc. (MYGN) reports that Jennifer Lynne Fox, Chief Legal & Corp Strategy, received a one-time retention award of 139,267 non-qualified stock options on November 6, 2026. The options have a $5.92 per-share exercise price and vest and become exercisable in full on November 6, 2029, subject to her continued service through that date and the plan and award-agreement terms. They expire November 6, 2036.

Insider Trade Summary

Grant/Award: 139,267 shares

Grant/Award 1 txn

Insider Fox Jennifer Lynne

Role Chief Legal & Corp Strategy

Type	Security	Shares	Price	Value
Grant/Award	Time-Based Stock Option F1, F2	139,267	$0.00	$0.00

Holdings After Transaction: Time-Based Stock Option — 139,267 options (Direct)

Footnotes (2)

1. F1. Represents a one-time non-qualified stock option granted as a retention award under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement.
2. F2. The exercise price equals the closing price of the Issuer's common stock on November 6, 2026, the grant date.

Key Figures

Options granted: 139,267 options Exercise price: $5.92 per share Vesting and exercisability: November 6, 2029 +1 more

4 metrics

Options granted 139,267 options One-time retention award; underlying security is common stock.

Exercise price $5.92 per share Equals the common stock closing price on the grant date, November 6, 2026.

Vesting and exercisability November 6, 2029 The options vest and become exercisable in full, subject to continued service through that date and the plan and award-agreement terms.

Expiration date November 6, 2036 Expiration date for the options.

Key Terms

non-qualified stock option, retention award, vests, exercisable

4 terms

non-qualified stock option financial

"one-time non-qualified stock option granted as a retention award"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

retention award financial

"granted as a retention award"

vests financial

"option vests and becomes exercisable in full"

exercisable financial

"becomes exercisable in full on November 6, 2029"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did MYGN's Chief Legal & Corp Strategy receive?

Jennifer Lynne Fox received 139,267 non-qualified stock options with a $5.92 per-share exercise price on November 6, 2026. The one-time grant was described as a retention award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fox Jennifer Lynne

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal & Corp Strategy

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Time-Based Stock Option(1)	$5.92(2)	11/06/2026		A		139,267		11/06/2029	11/06/2036	Common Stock	139,267	$0	139,267	D

Explanation of Responses:

1. Represents a one-time non-qualified stock option granted as a retention award under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement.

2. The exercise price equals the closing price of the Issuer's common stock on November 6, 2026, the grant date.

Remarks:

	By: Justin Hunter For: Jennifer Lynne Fox	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)